A New Switch for TGFβ in Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Transforming growth factor beta (TGFβ) exhibits dichotomous roles in tumor progression.
• Initially, TGFβ signaling inhibits proliferation and promotes apoptosis in normal/premalignant cells.
• Conversely, in late-stage cancers, TGFβ can enhance epithelial-to-mesenchymal transition, stemness, and metastasis.

Purpose of the Study:

• To review the context-dependent determinants that switch TGFβ signaling from proapoptotic to prometastatic.
• To elucidate mechanisms by which tumor cells manipulate TGFβ responses for progression.
• To highlight novel theranostic targets for anticancer strategies.

Main Methods:

• Literature review of recent findings on TGFβ signaling.
• Analysis of cellular contextual determinants and their binding partners (e.g., Smads).
• Examination of molecular mechanisms underlying TGFβ-mediated prometastatic switch.

Main Results:

• Cellular context, particularly Smad binding partners like PSPC1, KLF5, 14-3-3ζ, and C/EBPβ, dictates TGFβ's function.
• Tumor cells exploit these determinants to shift TGFβ from a tumor-suppressive to a tumor-promoting pathway.
• Altered expression of determinants and effectors during tumor progression signifies a prometastatic switch.

Conclusions:

• TGFβ's dual role presents a challenge for cancer therapy development.
• Contextual determinants are critical for switching TGFβ responses.
• Aberrant prometastatic molecular switches offer potential new theranostic targets for cancer treatment.